Upcoming event

Risks and benefits of partial nephrectomy performed with limited or with zero ischaemia time

BJU International, March 2023

Oncological outcomes of delayed nephrectomy after optimal response to immune checkpoint inhibitors for metastatic renal cell carcinoma

European Urology Oncology, October 2023

Local treatment of recurrent renal cell carcinoma may have a significant survival effect across all risk-of-recurrence groups

European Urology Open Science, January 2023

Three-dimensional model-assisted minimally invasive partial nephrectomy: A systematic review with meta-analysis of comparative studies

European Urology Oncology, December 2022

A Phase II study of neoadjuvant axitinib for reducing the extent of venous tumour thrombus in clear cell renal cell cancer with venous invasion (NAXIVA)

British Journal of Cancer, June 2022

Development and validation of a nomogram predicting intraoperative adverse events during robot-assisted partial nephrectomy

European Urology Focus, September 2022

Stereotactic ablative radiation for systemic therapy–naïve oligometastatic kidney cancer

European Urology Oncology, August 2022

Nivolumab, nivolumab–ipilimumab, and VEGFR-tyrosine kinase inhibitors as first-line treatment for metastatic clear-cell renal cell carcinoma (BIONIKK): a biomarker-driven, open-label, non-comparative, randomised, phase 2 trial

The Lancet Oncology, May 2022

What happens to the preserved renal parenchyma after clamped partial nephrectomy?

European Urology, May 2022

Nivolumab plus ipilimumab with or without live bacterial supplementation in metastatic renal cell carcinoma: a randomized phase 1 trial

Nature Medicine, February 2022

The Clinicopathologic and Molecular Landscape of Clear Cell Papillary Renal Cell Carcinoma: Implications in Diagnosis and Management

European Urology, Volume 79, Issue 4, April 2021, Pages 468-477